نتائج البحث

Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth.

• Authors : Chilamakuri, Rameswari¹ (AUTHOR); Agarwal, Saurabh¹ (AUTHOR)

• Source: Pharmaceuticals (14248247). Oct2024, Vol. 17 Issue 10, p1350. 15p.

تفاصيل العنوان

Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth

• Authors : Rameswari Chilamakuri; Saurabh Agarwal

Subjects: tivantinib; ARQ197; c-MET

• Source: Pharmaceuticals, Vol 17, Iss 10, p 1350 (2024)

تفاصيل العنوان

TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) (TIMES)

• Source: TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage

تفاصيل العنوان

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

• Authors : Armando Santoro, MD, Medical Doctor - Oncologist

• Source: A Single-Arm Phase II Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects With Locally Advanced or Metastatic Colorectal Cancer

تفاصيل العنوان

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors

• Authors : Liu, Stephen V; Groshen, Susan G; Kelly, Karen

Subjects: Biomedical and Clinical Sciences; Oncology and Carcinogenesis; Lung Cancer

• Source: Cancer Chemotherapy and Pharmacology. 82(4)

تفاصيل العنوان

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy (METIV-HCC)

• Authors : ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

• Source: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior

تفاصيل العنوان

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

• Source: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

تفاصيل العنوان

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

• Authors : Armando Santoro, MD, Principal Investigators

• Source: Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a

تفاصيل العنوان

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

• Authors : Shankun Zhao; Weizhou Wu; Hao Jiang

Subjects: tivantinib; MET inhibitor; hepatocellular carcinoma

• Source: Frontiers in Immunology, Vol 12 (2021)

تفاصيل العنوان

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

• Authors : ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

• Source: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous,

تفاصيل العنوان